119 related articles for article (PubMed ID: 12634513)
1. Do atypical antipsychotics fail to exert cognitive sparing effects?
Papageorgiou C; Oulis P; Vasios C; Matsopoulos GK; Uzunoglu N; Rabavilas A; Christodoulou GN
Neuroreport; 2003 Mar; 14(3):505-9. PubMed ID: 12634513
[TBL] [Abstract][Full Text] [Related]
2. P300 alterations in schizophrenic patients experiencing auditory hallucinations.
Papageorgiou C; Oulis P; Vasios C; Kontopantelis E; Uzunoglu N; Rabavilas A; Christodoulou GN
Eur Neuropsychopharmacol; 2004 May; 14(3):227-36. PubMed ID: 15056482
[TBL] [Abstract][Full Text] [Related]
3. Some aspects of psychodynamic response to novel atypical antipsychotics.
Murawiec S; Taflińska D; Tafliński T
Harv Rev Psychiatry; 1999; 7(4):241-2. PubMed ID: 10579106
[No Abstract] [Full Text] [Related]
4. Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.
Sharma T; Hughes C; Soni W; Kumari V
Psychopharmacology (Berl); 2003 Sep; 169(3-4):398-403. PubMed ID: 12845415
[TBL] [Abstract][Full Text] [Related]
5. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
6. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications.
Light GA; Geyer MA; Clementz BA; Cadenhead KS; Braff DL
Am J Psychiatry; 2000 May; 157(5):767-71. PubMed ID: 10784470
[TBL] [Abstract][Full Text] [Related]
7. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
Bilder RM; Goldman RS; Volavka J; Czobor P; Hoptman M; Sheitman B; Lindenmayer JP; Citrome L; McEvoy J; Kunz M; Chakos M; Cooper TB; Horowitz TL; Lieberman JA
Am J Psychiatry; 2002 Jun; 159(6):1018-28. PubMed ID: 12042192
[TBL] [Abstract][Full Text] [Related]
8. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.
Smith RC; Infante M; Singh A; Khandat A
Int J Neuropsychopharmacol; 2001 Sep; 4(3):239-50. PubMed ID: 11669086
[TBL] [Abstract][Full Text] [Related]
9. [Effect of olanzapine treatment on cognitive functions in patients with schizophrenia].
Radziwiłłowicz P; Radziwiłłowicz W; Lis J
Psychiatr Pol; 2002; 36(6):967-87. PubMed ID: 12725025
[TBL] [Abstract][Full Text] [Related]
10. P300 and symptom improvement in schizophrenia.
Gallinat J; Riedel M; Juckel G; Sokullu S; Frodl T; Moukhtieva R; Mavrogiorgou P; Nisslé S; Müller N; Danker-Hopfe H; Hegerl U
Psychopharmacology (Berl); 2001 Oct; 158(1):55-65. PubMed ID: 11685384
[TBL] [Abstract][Full Text] [Related]
11. A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine.
Stip E; Remington GJ; Dursun SM; Reiss JP; Rotstein E; MacEwan GW; Chokka PR; Jones B; Dickson RA;
J Clin Psychopharmacol; 2003 Aug; 23(4):400-4. PubMed ID: 12920417
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients.
Swartz JR; Ananth J; Smith MW; Burgoyne KS; Gadasally R; Arai Y
J Clin Psychiatry; 1999 Feb; 60(2):119-21. PubMed ID: 10084639
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.
Krakowski MI; Czobor P; Nolan KA
J Clin Psychopharmacol; 2008 Oct; 28(5):485-93. PubMed ID: 18794642
[TBL] [Abstract][Full Text] [Related]
14. Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity.
Juckel G; Gallinat J; Riedel M; Sokullu S; Schulz C; Möller HJ; Müller N; Hegerl U
Schizophr Res; 2003 Nov; 64(2-3):115-24. PubMed ID: 14613676
[TBL] [Abstract][Full Text] [Related]
15. Atypical antipsychotic drugs and long-term outcome in schizophrenia.
Weiden P; Aquila R; Standard J
J Clin Psychiatry; 1996; 57 Suppl 11():53-60. PubMed ID: 8941171
[TBL] [Abstract][Full Text] [Related]
16. Effects of clozapine on auditory event-related potentials in schizophrenia.
Umbricht D; Javitt D; Novak G; Bates J; Pollack S; Lieberman J; Kane J
Biol Psychiatry; 1998 Oct; 44(8):716-25. PubMed ID: 9798075
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.
Keck PE; Strakowski SM; McElroy SL
J Clin Psychiatry; 2000; 61 Suppl 3():4-9. PubMed ID: 10724127
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.
Bitter I; Dossenbach MR; Brook S; Feldman PD; Metcalfe S; Gagiano CA; Füredi J; Bartko G; Janka Z; Banki CM; Kovacs G; Breier A;
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):173-80. PubMed ID: 14687871
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of olanzapine: an overview of pivotal clinical trials.
Beasley CM; Tollefson GD; Tran PV
J Clin Psychiatry; 1997; 58 Suppl 10():7-12. PubMed ID: 9265910
[TBL] [Abstract][Full Text] [Related]
20. Clozapine to olanzapine.
Millson RC; Delva NJ
Am J Psychiatry; 1999 Jul; 156(7):1121. PubMed ID: 10401476
[No Abstract] [Full Text] [Related]
[Next] [New Search]
